Table 2.

Details of octreotide therapy

Case	Indication for octreotide	Age at start of treatment (days)	Duration of treatment (days)	Route and frequency	Duration of drainage	Initial dose	Days to initiate octreotide after effusion	Maximum dose	Adverse effects	Response
1	Chylothorax [acquired] Bilateral	21	22	Intravenous continuous infusion	28	1 µg/kg/h	6	10 µg/kg/h	a. Transient decrease in thyroid-stimulating hormone b. Transient hyperglycaemia	Yes
2	Chylothorax [acquired] Bilateral	18	23	Intravenous continuous infusion	26	1 µg/kg/h	4	10 µg/kg/h	a. Transient decrease in free thyroxine b. Transient hyperglycaemia	No
3	Chylous ascites [acquired]	82	7	Intravenous continuous infusion	27	1 µg/kg/h	20	4 µg/kg/h	No adverse effect	Yes
4	Chylothorax [acquired] Bilateral	72	26	Intravenous continuous infusion	53	1 µg/kg/h	27	10 µg/kg/h	a. Transient hyperglycaemia b. Transient decrease in free thyroxine and thyroid-stimulating hormone	Yes
5	Chylothorax [congenital] Bilateral	17	9	Intravenous continuous infusion	25	1 µg/kg/h	18	10 µg/kg/h	a. Decrease in free T4	No
6	Chylothorax [acquired] Unilateral left	16	13	Intravenous continuous infusion	12	1 µg/kg/h	8	4 µg/kg/h	a. Transient hyperglycaemia	Yes
7	Chylothorax [congenital] Bilateral	25	29	Intravenous continuous infusion	65	1 µg/kg/h	24	8 µg/kg/h	No adverse effect	No
8	Chylous ascites [congenital]	21	28	Intravenous continuous infusion	42	1 µg/kg/h	16	8 µg/kg/h	a. Transient hyperglycaemia	No
9	Chylothorax [acquired] Bilateral	68	66	Intravenous continuous infusion	57	1 µg/kg/h	22	8 µg/kg/h	a. Transient hyperglycaemia	No
10	Chylothorax [idiopathic] Unilateral left	64	10	Subcutaneous injection in three divided doses	40	25 µg/kg/day	13	117 µg/kg/day	a. Decrease in free thyroxine and thyroid-stimulating hormone	No
11	Chylothorax [congenital] Unilateral right	24	5	Subcutaneous injection in three divided doses	23	11 µg/kg/day	10	24 µg/kg/day	No adverse effects	No